Clinical Trials Logo

MCD clinical trials

View clinical trials related to MCD.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04009668 Completed - Clinical trials for Focal Segmental Glomerulosclerosis

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Start date: October 2, 2019
Phase: Phase 2
Study type: Interventional

The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).